Artamonova Nastasiia, Kafka Mona, Faiss Laura, Avetisyan David, Puche Sanz Ignacio, La Bombarda Giulia, Iacono Gennaio, Zattoni Fabio, Steiner Eberhard, D'Elia Caroline, Pycha Armin, Ladurner Michael, Jagodic Samed, Gandaglia Giorgio, Heidegger Isabel
Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
UGC Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Eur Urol Open Sci. 2024 Oct 8;69:105-111. doi: 10.1016/j.euros.2024.09.005. eCollection 2024 Nov.
Collagen biosynthesis is intricately involved in the development and progression of solid tumors. Renin-angiotensin system inhibitors (RASi) impede TGF-β-mediated collagen synthesis in tumors by hindering activation of the angiotensin receptor. Our aim was to investigate a potential association between RASi use and the aggressiveness of prostate cancer (PCa).
We conducted a retrospective multicenter analysis for a cohort of 1250 patients with PCa who underwent radical prostatectomy (RP) between 1990 and 2023 in four European high-volume centers. The study cohort comprised 625 RASi-treated patients and 625 age-matched RASi-naïve patients. Data for various parameters were collected, including age at RP, body mass index (BMI), prostate volume, prostate-specific antigen (PSA), percentage of free PSA, Gleason score (GS) at biopsy and RP, TNM stage, and the rate of biochemical recurrence (BCR). Clinical parameters for patients with and without RASi treatment were documented. Differences between the groups were compared using a Mann-Whitney U test and χ tests. Survival analyses were performed using the Kaplan-Meier method.
As expected, the RASi group had higher BMI levels than the RASi-naïve group ( < 0.001). However, RASi use was not associated with key markers of PCa aggressiveness such as GS upgrading from biopsy to RP ( = 0.089), surgical margin status ( = 0.109), and lymph node involvement ( = 0.33). Moreover, there were no significant differences between the groups in BCR incidence ( = 0.258) or the time to BCR ( = 0.683).
Our findings indicate that RASi therapy does not have a significant effect on the biological aggressiveness of PCa.
We analyzed data for 1250 patients with prostate cancer and found that the use of a commonly prescribed high blood pressure medication was not associated with a less aggressive form of localized prostate cancer.
胶原蛋白生物合成与实体瘤的发生发展密切相关。肾素-血管紧张素系统抑制剂（RASi）通过阻碍血管紧张素受体的激活来抑制肿瘤中转化生长因子-β介导的胶原蛋白合成。我们的目的是研究RASi的使用与前列腺癌（PCa）侵袭性之间的潜在关联。
我们对1990年至2023年期间在四个欧洲大型中心接受根治性前列腺切除术（RP）的1250例PCa患者进行了回顾性多中心分析。研究队列包括625例接受RASi治疗的患者和625例年龄匹配的未接受RASi治疗的患者。收集了各种参数的数据，包括RP时的年龄、体重指数（BMI）、前列腺体积、前列腺特异性抗原（PSA）、游离PSA百分比、活检和RP时的 Gleason评分（GS）、TNM分期以及生化复发（BCR）率。记录了接受和未接受RASi治疗患者的临床参数。使用Mann-Whitney U检验和χ检验比较组间差异。使用Kaplan-Meier方法进行生存分析。
正如预期的那样，RASi组的BMI水平高于未接受RASi治疗的组（<0.001）。然而，RASi的使用与PCa侵袭性的关键标志物无关，如从活检到RP的GS升级（=0.089）、手术切缘状态（=0.109）和淋巴结受累情况（=0.33）。此外，两组在BCR发生率（=0.258）或BCR发生时间（=0.683）方面没有显著差异。
我们的研究结果表明，RASi治疗对PCa的生物学侵袭性没有显著影响。
我们分析了1250例前列腺癌患者的数据，发现使用一种常用的高血压药物与局限性前列腺癌侵袭性较低的形式无关。
